Balchem Corp BCPC
We take great care to ensure that the data presented and summarized in this overview for BALCHEM CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCPC
View all-
Black Rock Inc. New York, NY4.9MShares$812 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.92MShares$649 Million0.01% of portfolio
-
Apg Asset Management N.V. Amsterdam, P72.77MShares$458 Million3.1% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.36MShares$224 Million1.18% of portfolio
-
State Street Corp Boston, MA1.23MShares$204 Million0.01% of portfolio
-
Conestoga Capital Advisors, LLC1.18MShares$195 Million2.86% of portfolio
-
Geode Capital Management, LLC Boston, MA929KShares$154 Million0.01% of portfolio
-
Geneva Capital Management LLC780KShares$129 Million2.33% of portfolio
-
Morgan Stanley New York, NY768KShares$127 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX643KShares$106 Million0.03% of portfolio
Latest Institutional Activity in BCPC
Top Purchases
Top Sells
About BCPC
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
Insider Transactions at BCPC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 31
2024
|
Job Leonard Van Gunsteren SVP and GM, Specialty Products |
SELL
Open market or private sale
|
Direct |
7,750
-47.58%
|
$1,395,000
$180.05 P/Share
|
Jul 31
2024
|
Job Leonard Van Gunsteren SVP and GM, Specialty Products |
BUY
Exercise of conversion of derivative security
|
Direct |
7,750
+21.45%
|
$457,250
$59.68 P/Share
|
Jul 30
2024
|
William A. Backus VP & Chief Accounting Officer |
SELL
Open market or private sale
|
Indirect |
904
-87.26%
|
$160,008
$177.1 P/Share
|
Jul 30
2024
|
William A. Backus VP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,900
-23.19%
|
$698,100
$179.86 P/Share
|
Jul 30
2024
|
William A. Backus VP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+30.5%
|
$327,600
$84.09 P/Share
|
Jul 27
2024
|
Hatsuki Miyata EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-10.65%
|
$110,880
$180.78 P/Share
|
May 10
2024
|
Michael Robert Sestrick SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,929
-28.34%
|
$297,066
$154.45 P/Share
|
May 08
2024
|
David B Fischer |
SELL
Open market or private sale
|
Direct |
5,000
-18.87%
|
$765,000
$153.37 P/Share
|
Mar 08
2024
|
Michael Brent Tignor SVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
5,339
-21.84%
|
$838,223
$157.65 P/Share
|
Mar 08
2024
|
Michael Brent Tignor SVP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,200
+23.45%
|
$357,000
$85.4 P/Share
|
Mar 04
2024
|
Matthew David Wineinger |
SELL
Open market or private sale
|
Direct |
1,333
-17.79%
|
$207,948
$156.89 P/Share
|
Feb 26
2024
|
William A. Backus VP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,000
-21.15%
|
$1,085,000
$155.38 P/Share
|
Feb 23
2024
|
William A. Backus VP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
9,180
-23.22%
|
$1,432,080
$156.55 P/Share
|
Feb 23
2024
|
William A. Backus VP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,180
+18.65%
|
$725,220
$79.49 P/Share
|
Feb 22
2024
|
Theodore L Harris Chairman, President & CEO |
SELL
Open market or private sale
|
Direct |
34,350
-12.91%
|
$5,289,900
$154.49 P/Share
|
Feb 22
2024
|
Theodore L Harris Chairman, President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,350
+15.52%
|
$1,957,950
$57.86 P/Share
|
Feb 21
2024
|
William A. Backus VP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
15,000
-18.51%
|
$2,310,000
$154.64 P/Share
|
Feb 21
2024
|
William A. Backus VP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+34.95%
|
$900,000
$60.85 P/Share
|
Feb 21
2024
|
Theodore L Harris Chairman, President & CEO |
SELL
Open market or private sale
|
Direct |
29,679
-8.54%
|
$4,570,566
$154.37 P/Share
|
Feb 21
2024
|
Michael Robert Sestrick SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
11,100
-62.23%
|
$1,698,300
$153.21 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 58.4K shares |
---|---|
Exercise of conversion of derivative security | 85.5K shares |
Open market or private sale | 132K shares |
---|---|
Payment of exercise price or tax liability | 28.7K shares |